Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Hemoglobin F" patented technology

Fetal hemoglobin; major component of hemoglobin in the fetus; it has two alpha and two gamma polypeptide subunits in comparison to normal adult hemoglobin, which has two alpha and two beta polypeptide subunits.

Hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit and preparation method and detection method thereof

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.
Owner:HANGZHOU HUIYUANTAI MEDICAL DEVICES

Hemoglobin-haptoglobin complexes

Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein.
Owner:THERAPURE BIOPHARMA INC

Method for measuring glycosylated hemoglobin by isotope dilution mass spectrometry

The present invention discloses a method for measuring glycosylated hemoglobin by isotope dilution liquid chromatography-tandem mass spectrometry. The method comprises the following steps: 1) a mole <15>N-HbA1c-<13>C and b mole <15>N-HbA0-<13>C both are added into a standard substance solution and a to-be-tested sample, the standard substance solution and the to-be-tested sample pass by a solid phase extraction column to obtain a to-be-loaded standard substance and a to-be-loaded to-be-tested sample, <15>N-HbA1c-<13>C is a hexapeptide chain at the N terminal of an isotope 15N and 13C-labeled glycosylated hemoglobin beta chain, the <15>N-HbA0-<13>C is a hexapeptide chain at the N terminal of an isotope 15N and 13C-labeled non-glycosylated hemoglobin beta chain, and a and b both are greater than 0; 2) the to-be-loaded standard substance and the to-be-loaded to-be-tested sample are respectively detected by a liquid chromatography-tandem mass spectrometer; and 3) the content of the glycated hemoglobin in the to-be-tested sample can be obtained from the testing results of the step 2). The method is simple in operation, is more accurate and precise than a mass spectrometric method recommended by IFCC, has good specificity and sensitivity, and is expected to become a decisive reference method for the determination of the glycated hemoglobin.
Owner:BEIJING CHAOYANG HOSPITAL CAPITAL MEDICAL UNIV

Low oxygen affinity mutant hemoglobins

Non-naturally occurring mutant hemoglobins rHb (.beta.N108Q) and rHb (.beta.L105W) are provided that have a lower oxygen affinity than that of native hemoglobin, but high cooperativity in oxygen binding. rHb (.beta.N108Q) also exhibits enhanced stability against autoxidation. The mutant hemoglobins are preferably produced by recombinant DNA techniques. Such mutant hemoglobins may be used as a component of a blood substitute and hemoglobin therapeutics.
Owner:CARNEGIE MELLON UNIV

Function of a haptoglobin-haemoglobin receptor and the uses thereof

The present invention relates to haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof or a mimic thereof being operably linked to a substance and capable of binding a CD163 receptor. Furthermore, the invention relates to a CD163 variant, membrane bound or soluble, capable of binding at least one haptoglobin-haemoglobin (Hp-Hb) complex, and the use of the Hp-Hb complex and the CD163 receptor for therapy.
Owner:DELIVER PHARMA APS

Immunocompetent human placental polypeptides derived from hemoglobin

The invention relates to active polypeptides from a human placenta, which are derived from hemoglobin. The invention also relates to a composition comprising the polypeptides and application of the composition. A small-molecule substance with a molecular weight below 10KD in the human placenta is extracted from the human placenta by using a positive hepatitis B virus (HBV) surface antibody (HBsAb) to prepare injections including a liquid injection and a powder injection. According to the invention, the polypeptides in an extract are preliminarily analyzed by using a method of proteomics to obtain 5 types of human placental immunocompetent polypeptides derived from hemoglobin, and experimental studies show that the human placental immunocompetent polypeptides have immunological competence.
Owner:SHINEWAY PHARMA GRP LTD

Pluri-negative-charge hemoglobin alpha subunit

The invention relates to a pluri-negative-charge hemoglobin alpha subunit, and relates to a component of a hemoglobin red blood cell substitute artificial blood. The invention relates to the technical field of biomedicine. The pluri-negative-charge hemoglobin alpha subunit is a fusion protein composed of human serum albumin and human hemoglobin alpha subunit. The human serum albumin and human hemoglobin are connected through connecting peptide. The preparation method comprises the following steps: with a PCR amplification method or a chemical total synthesis method, a fusion protein polypeptide chain amino acid sequence is synthesized; the fusion protein polypeptide chain amino acid sequence is cloned to a prokaryotic expression vector; the expression vector is transformed into cells of an expression system; with an induction method, effective cells are identified; and the cells are subjected to separation and purification. The fusion protein has large molecular weight and carries a lot of negative charges. With the two factors, even a fusion protein in the form of a monomer cannot pass kidney filtration, such that side effect to ahuman body is reduced. The human serum albumin can be bonded with heme. Therefore, when the fusion protein is used for preparing artificial blood, higher bonding capability and higher oxygen transportation capacity are provided.
Owner:王子元 +2

Nucleic acid vectors comprising DNase I hypersensitive sites

The present invention provides novel recombinant nucleic acid vectors which may be used to produce alpha -globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The present invention also provides for the transgenic animals which contain these recombinant nucleic acid vectors. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the beta -globin locus together with a gene of interest. According to various embodiments of the invention, the vectors may be used to create transgenic animals or to transfect cells in culture. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human alpha -globin gene is used to create transgenic animals which produce human alpha -globin protein in erythroid tissues, including red blood cells. In a preferred specific embodiment of the invention, transgenic animals are created which comprise human alpha -globin and beta -globin genes, each under the transcriptional influence of two beta -globin locus DNase hypersensitivity sites; these transgenic animals express human hemoglobin in their erythroid tissues, and can be used to produce human hemoglobin in quantity.
Owner:UAB RES FOUND +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products